These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26614588)

  • 1. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies.
    Coudeville L; Baurin N; Vergu E
    Vaccine; 2016 Dec; 34(50):6417-6425. PubMed ID: 26614588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
    Coudeville L; Baurin N; L'Azou M; Guy B
    Vaccine; 2016 Dec; 34(50):6426-6435. PubMed ID: 27601343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dengue fever: from disease to vaccination].
    Teyssou R
    Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
    Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
    J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a tetravalent dengue vaccine in children in Latin America.
    Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
    N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
    Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
    Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
    Guy B; Briand O; Lang J; Saville M; Jackson N
    Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projected Impact of Dengue Vaccination in Yucatán, Mexico.
    Hladish TJ; Pearson CA; Chao DL; Rojas DP; Recchia GL; Gómez-Dantés H; Halloran ME; Pulliam JR; Longini IM
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004661. PubMed ID: 27227883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
    Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
    Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current issues in the economics of vaccination against dengue.
    Tozan Y
    Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sanofi’s successful Phase 3 trials may lead to first-ever dengue vaccine in 2015.
    Hum Vaccin Immunother; 2014; 10(12):3427. PubMed ID: 25864560
    [No Abstract]   [Full Text] [Related]  

  • 15. A role for vector control in dengue vaccine programs.
    Christofferson RC; Mores CN
    Vaccine; 2015 Dec; 33(50):7069-74. PubMed ID: 26478199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach.
    Coudeville L; Baurin N; Olivera-Botello G
    Expert Rev Vaccines; 2018 Aug; 17(8):753-763. PubMed ID: 30063839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination models and optimal control strategies to dengue.
    Rodrigues HS; Monteiro MT; Torres DF
    Math Biosci; 2014 Jan; 247():1-12. PubMed ID: 24513243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue serotype immune-interactions and their consequences for vaccine impact predictions.
    Lourenço J; Recker M
    Epidemics; 2016 Sep; 16():40-8. PubMed ID: 27663790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
    El Fezzazi H; Branchu M; Carrasquilla G; Pitisuttithum P; Perroud AP; Frago C; Coudeville L
    Am J Trop Med Hyg; 2017 Dec; 97(6):1898-1903. PubMed ID: 29141713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling dengue with vaccines in Thailand.
    Chao DL; Halstead SB; Halloran ME; Longini IM
    PLoS Negl Trop Dis; 2012; 6(10):e1876. PubMed ID: 23145197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.